Hoffmann-la Roche Inc.

Ptc Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Siena Biotech S.p.a.

Emmanuel Pinard

Robert Narquizian

Marie-Paule Heitz Neidhart

Synese Jolidon

Alexander Alanine

Roger David Norcross

Matthias Heinrich Nettekoven

Mark Rogers-Evans

Henner Knust

Bernd Buettelmann

Rene Wyler

Georg Jaeschke

Olivier Roche

Hasane Ratni

Sabine Kolczewski

Gary Mitchell Karp

Henri Stalder

Nikolai A Naryshkin

Hongyan Qi

Marla L Weetall

Jana Narasimhan

Matthew G Woll

Amal Dakka

Ren&eacute; Wyler

Luke Green

Ellen Welch

Xiaoyan Zhang

Soongyu Choi

Nanjing Zhang

Xin Zhao

Tianle Yang

Katrin Groebke Zbinden

Anthony A Turpoff

Bernd Buttelmann

Hans Hilpert

Thomas Johannes Woltering

Wolfgang Wostl

Bernd B&uuml;ttelmann

Daniela Alberati-Giani

Andrew William Thomas

Luca Claudio Gobbi

Simona Maria Ceccarelli

Parichehr Malherbe

Serge Burner

Thomas Ryckmans

Werner Neidhart

Patrizio Mattei

Hans G Richter

Rainer Eugen Martin

Daniel Hunziker

Wolfgang Guba

Guangming Chen

Holger Kuehne

Alexander Mayweg

Vincent Mutel

Thomas Luebbers

Markus Rudolph

David Banner

Harald Mauser

Jerome Hert

Giuseppe Cecere

Andrea Cesura

Andreas Koblet

Chang-Sun Lee

Stephan Rover

Maria-Clemencia Hernandez

Chunshi Li

Sergey Paushkin

Daniela Alberati

Theresa Maria Ballard

Song Xiao Huang

Gerhard Trube

Gunther Fischer

Anne Bourson

Herve Schaffhauser

Henri Stadler

Roland Jakob-Roetne

Patrick Schnider

Alexander Flohr

Caterina Bissantz

Raffaello Masciadri

Benoit Hornsperger

Erwin Goetschi

Urs Schwitter

Roland Humm

Bernhard Fasching

Olaf Grassmann

Valerie Runtz-Schmitt

Ralph Diodone

Sandra Steiner

Edilio Borroni

Holger Fischer

Eoin Power

Franziska E Rohrer

Emanuele Gabellieri

Alessandra Polara

Thomas Hartung

Joerg Huwyler

Jean-Baptiste Blanc

Andre Bubendorf

The invention provides novel compounds having the general formula (I) or (II) wherein R, R, R, R, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

Isoxazolyl ether derivatives as GABA&#x3b1;5 PAM

Provided herein are compounds of Formula (I): and forms thereof, wherein w, w, w, w, w, wand ware as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.

Compounds for treating spinal muscular atrophy

The invention provides novel compounds having the general formula (I) wherein R, R, R, Rand W are as defined herein, compositions including the compounds and methods of using the compounds.

Phenoxymethyl derivatives

Compounds having the formula (I) wherein R, R, R, R, R, R, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

Provided herein are compounds of Formula (I): 

The present invention provides compounds of formula (I) wherein A, B, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments. 

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

The present invention provides compounds of formula (I) 

Substituted imidazo[1,2-&#x3b1;]pyrazines for treating spinal muscular atrophy

The present invention relates to compounds of formula wherein R, Y, Y, X, R and n are as defined herein.

Pyrrolopyridine or pyrazolopyridine derivatives

Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

The invention is related to compounds, which are GlyT1 inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis.

GlyT1 inhibitors for use in the treatment of hematological disorders

The present invention relates to compounds of formula  The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

Flouro-naphthyl derivatives

The present invention relates to compounds of formula I or pharmaceutically acceptable addition salts, racemic mixtures or the corresponding enantiomers and optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain and sleep disorder.

Indol and indazol derivatives

Growing community of inventors

Linsdorf, France

Emmanuel Pinard